Morning edition · Wednesday, 28 October 2026
Start the HPV jab at nine, and more children finish it by thirteen
A randomised trial in 31 paediatric practices moved the first dose two years earlier. Completion by 13 rose from 45.1% to 61.6%. No new vaccine required.
Most health news is about something new: a molecule, a device, a programme. This one is about a calendar. Researchers led by Sean O’Leary of the University of Colorado and Children’s Hospital Colorado tested what happens when paediatric practices offer the human papillomavirus (HPV) vaccine at ages 9 to 10 instead of 11 to 121. The study was presented at IDWeek, the Infectious Diseases Society of America’s annual meeting, held in Washington from 21 to 24 October1.
The design was sturdy for a question this practical. It was a cluster-randomised trial in 31 paediatric practices in Colorado and California, running from 2021 to 2026: 16 practices were assigned to start at 9–10 and 15 at 11–121.
The results are the kind you can read without a statistician. By age 13, 77.1% of children in the earlier arm had started the series and 61.6% had completed it, against 67.0% and 45.1% in the later arm1. Desk arithmetic: 16.5 percentage points more children fully vaccinated by 13. The median age at completion was 12.2 years in the earlier arm and 13.3 in the later one1.
Why would two years make that much difference? The report does not say, and this desk will not guess beyond the obvious: a longer runway leaves more room for the second appointment, the missed visit and the rescheduled one. A series is only as good as the share of people who finish it.
“Lowering the age of vaccination holds promise for increasing the number of people protected against HPV, particularly as related cancers are on the rise,” O’Leary said1. The vaccine is the same, the price is the same and the doctors are the same. What changed is when the reminder goes out. If you have a child approaching ten, it is a fair question to put to your paediatrician.
What to watch
- Whether the full paper, presented as a conference study, follows in a peer-reviewed journal1.
- Whether vaccine committees and paediatric guidelines that still anchor the first dose at 11–12 take up the earlier age.
The cheapest health reform is often a different date on the same schedule.
Sources
- IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13 (HealthDay, on O'Leary et al., IDWeek 2026) — Medical Xpress, 27 Oct 2026.
Every figure in this piece traces to a source above or to the desk’s own arithmetic on those sources, marked as such. Quotations are short and attributed. Spot an error? Write to the desk; corrections are logged on the method page.
Commentary for information only. Not investment, legal, tax, medical or political advice. Not an offer or solicitation. Analysis may be incomplete or wrong. Charts show published public data, not a trading feed; binding numbers live with the institutions that publish them.